Novavax Announces Management Promotions
June 19 2014 - 4:10PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical
company focused on the discovery, development, and
commercialization of recombinant nanoparticle vaccines and
adjuvants, announced today a number of promotions within its
management team.
John A. Herrmann III, J.D. has been named Senior Vice President,
General Counsel and Corporate Secretary. Mr. Herrmann joined
Novavax in March 2010 and is responsible for managing all of
Novavax' legal affairs, including its patent portfolio,
transactional and contractual matters, public securities filings,
and attending to all the duties of Corporate Secretary. Mr.
Herrmann also works with the company's senior management team to
define and develop corporate policies and procedures. Prior to
joining Novavax, Mr. Herrmann served as General Counsel at Ore
Pharmaceuticals and Deputy General Counsel at Gene Logic before it
became Ore Pharmaceuticals. Prior to joining Gene Logic, Mr.
Herrmann served as Senior Counsel for Celera Genomics and prior to
that as Senior Corporate Counsel at Baxter Healthcare in its Renal
Division. Mr. Herrmann received his B.A. in Political Science and
History from Brown University and his J.D. from the University of
Illinois.
Denise Courbron, M.S., PMP has been named Vice President, Global
Program Management to lead Novavax' program management efforts
covering all vaccine development programs. Ms. Courbron joined
Novavax in June 2010 as Executive Director, Global Program
Management and was instrumental in Novavax' being awarded its $179
million influenza development contract with HHS BARDA in February
2011. Prior to joining Novavax, Ms. Courbron held positions of
increasing responsibility in a number of companies in the vaccines
industry, including PharmAthene, Intercell USA, Iomai Corporation,
PPD, Baxter BioScience, GloboMax (ICON), and North American
Vaccine. Ms. Courbron received a B.A. in Political Science and
Spanish from Western Maryland College (McDaniel) and an M.S. in
Biotechnology Management from the University of Maryland University
College. Ms. Courbron is a certified Project Management
Professional (PMPTM).
"I am very pleased to announce the promotions of John and
Denise. Their contributions over the last number of years have been
critical to the success of the company. John has been irreplaceable
assisting the management team and the board to navigate the
regulatory, compliance, and corporate governance requirements of a
public company. Denise's long history of experience with government
contracts and project management has been integral to the
successful execution of our contract with HHS BARDA. I look forward
to their continued involvement in the success of the company," said
Stanley C. Erck, President and CEO.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biopharmaceutical company creating novel vaccines and vaccine
adjuvants to address a broad range of infectious diseases
worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine
candidates to efficiently and effectively respond to both known and
newly emergent diseases. Additional information about Novavax is
available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024